WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
When it is fully operational in all 14 WellPoint states, more than 21 million members will be eligible for the initiative to standardize cancer prescribing and lower drug costs.
You may also be interested in...
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.